A fast gene test during brain surgery to look for leftover IDH1 tumor cells
Official title: Residual IDH1-Mutant Tumor Cell Quantification Study
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study asks if a quick test during surgery can find tumor cells left behind.
Read our full plain-language summary
What the trial team says
This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.
Key facts
- Registry number
- NCT07219199
- Stage of testing
- Not applicable
- Conditions studied
- Glioma
Where it is running
This trial lists 1 site.
-
New York
- NYU Langone Health (New York)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.